Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data

Demirci, Zühal; ARSLAN DAVULCU, EREN; Arslan, Ayşenur; Keklik Karadağ, fatma; DEMIR, DERYA; Soyer, Nur; Sahin, Fahri; Saydam, Guray

Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data

Eren ARSLAN DAVULCU, (Sağlık Bilimleri Üniversitesi, Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, İstanbul, Türkiye)

Fatma KEKLİK, (Sağlık Bilimleri Üniversitesi, Tepecik Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, İzmir, Türkiye)

Ayşenur ARSLAN, (Osmaniye Devlet Hastanesi, Osmaniye, Türkiye)

Zühal DEMİRCİ, (Ege Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, İzmir, Türkiye)

Derya DEMİR, (Ege Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, İzmir, Türkiye)

Nur SOYER, (Ege Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, İzmir, Türkiye)

Fahri ŞAHİN, (Ege Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, İzmir, Türkiye)

Guray SAYDAM (Ege Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, İzmir, Türkiye)

Ege Tıp Dergisi

3 1

Yıl: 2023 Cilt: 62 Sayı: 2 Sayfa Aralığı: 266 - 271 Metin Dili: İngilizce İndeks Tarihi: 16-06-2023

Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data

Öz:

Aim: T-cell lymphomas are a subtype of Non-Hodgkin lymphoma with a poor prognosis and treatment options are limited. Pralatrexate, an antimetabolite drug, has been approved for the treatment of relapsed and refractory T-cell lymphoma. Materials and Methods: Our study retrospectively evaluated relapsed and refractory T-cell lymphoma patients who received pralatrexate in terms of efficacy and safety of the drug. Results: A total of 13 patients were recruited. The median age at diagnosis was 63 years. The most common histologic types were mycosis fungoides with large cell transformation (31%) and angioimmunoblastic T-cell lymphoma (31%). The median number of prior systemic therapies before pralatrexate was 2 (range 1-6). The most common side effect was mucositis (54%). The overall response rate was 38% (15% complete remission and 23% partial remission). The median OS was 32±6.5 months and PFS was 6.78±1.6 months. Conclusion: Our study provided real-world data on the efficacy and safety of pralatrexate and supports current literature. This drug has acceptable toxicity and significant effectiveness on peripheral T-cell lymphomas.

Anahtar Kelime: T-cell lymphoma lymphoma pralatrexate

Relaps ve refrakter T-hücreli lenfoma hastalarında pralatrexate kullanımı: gerçek yaşam verileri

Öz:

Amaç: T-hücreli lenfomalar, non-Hodgkin lenfomaların kötü prognozlu bir alt tipidir ve tedavi seçenekleri sınırlıdır. Bir antimetabolit ilaç olan pralatrexate, relaps ve refrakter T-hücreli lenfoma tedavisinde onaylanmıştır. Gereç ve Yöntem: Çalışmamızda pralatreksat alan relaps ve refrakter T-hücreli lenfoma hastaları ilacın etkinlik ve güvenliliği açısından retrospektif olarak değerlendirilmiştir. Bulgular: Toplam 13 hasta alındı. Tanı anındaki ortanca yaş 63 olarak bulundu. En yaygın histolojik tipler, büyük hücre transformasyonu gösteren mikozis fungoides (%31) ve anjiyoimmünoblastik T hücreli lenfomaydı (%31). Pralatreksattan önceki medyan sistemik tedavi sayısı 2’ydi (1-6 aralığında). En sık görülen yan etki mukozitti (%54). Genel yanıt oranı %38'di (%15 tam remisyon ve %23 kısmi remisyon). Ortanca OS 32±6,5 ay ve PFS 6,78±1,6 aydı. Sonuç: Çalışmamız, pralatreksatın etkinliği ve güvenliği hakkında gerçek dünya verileri sağlamıştır ve sonuçlar mevcut literatürü desteklemektedir. Toksisitesi kabul edilebilir düzeydedir ve periferik T-hücreli lenfomalar üzerinde önemli etkinliği vardır

Anahtar Kelime: T-hücreli lenfoma lenfoma paralatrexate

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
2. Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood 2014;123:2636- 44.
3. Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol 2011;2011:623924.
4. Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019;393:229-240.
5. Petrich AM, Rosen ST. Peripheral T-cell lymphoma: new therapeutic strategies. Oncology (Williston Park) 2013;27:878-84.
6. Toner LE, Vrhovac R, Smith EA, et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:924-32.
7. Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10- propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44:1027-35.
8. Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010;16:3648-58.
9. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-9.
10. Malik SM, Liu K, Qiang X, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2010;16:4921-7.
11. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
12. Bhurani M, Admojo L, Van Der Weyden C, et al. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Leuk Lymphoma 2021;62:330-6.
13. Hong JY, Yoon DH, Yoon SE, et al. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Sci Rep 2019;9(1):20302.

APA	ARSLAN DAVULCU E, Keklik Karadağ f, Arslan A, Demirci Z, DEMIR D, Soyer N, Sahin F, Saydam G (2023). Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. , 266 - 271.
Chicago	ARSLAN DAVULCU EREN,Keklik Karadağ fatma,Arslan Ayşenur,Demirci Zühal,DEMIR DERYA,Soyer Nur,Sahin Fahri,Saydam Guray Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. (2023): 266 - 271.
MLA	ARSLAN DAVULCU EREN,Keklik Karadağ fatma,Arslan Ayşenur,Demirci Zühal,DEMIR DERYA,Soyer Nur,Sahin Fahri,Saydam Guray Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. , 2023, ss.266 - 271.
AMA	ARSLAN DAVULCU E,Keklik Karadağ f,Arslan A,Demirci Z,DEMIR D,Soyer N,Sahin F,Saydam G Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. . 2023; 266 - 271.
Vancouver	ARSLAN DAVULCU E,Keklik Karadağ f,Arslan A,Demirci Z,DEMIR D,Soyer N,Sahin F,Saydam G Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. . 2023; 266 - 271.
IEEE	ARSLAN DAVULCU E,Keklik Karadağ f,Arslan A,Demirci Z,DEMIR D,Soyer N,Sahin F,Saydam G "Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data." , ss.266 - 271, 2023.
ISNAD	ARSLAN DAVULCU, EREN vd. "Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data". (2023), 266-271.

APA	ARSLAN DAVULCU E, Keklik Karadağ f, Arslan A, Demirci Z, DEMIR D, Soyer N, Sahin F, Saydam G (2023). Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. Ege Tıp Dergisi, 62(2), 266 - 271.
Chicago	ARSLAN DAVULCU EREN,Keklik Karadağ fatma,Arslan Ayşenur,Demirci Zühal,DEMIR DERYA,Soyer Nur,Sahin Fahri,Saydam Guray Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. Ege Tıp Dergisi 62, no.2 (2023): 266 - 271.
MLA	ARSLAN DAVULCU EREN,Keklik Karadağ fatma,Arslan Ayşenur,Demirci Zühal,DEMIR DERYA,Soyer Nur,Sahin Fahri,Saydam Guray Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. Ege Tıp Dergisi, vol.62, no.2, 2023, ss.266 - 271.
AMA	ARSLAN DAVULCU E,Keklik Karadağ f,Arslan A,Demirci Z,DEMIR D,Soyer N,Sahin F,Saydam G Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. Ege Tıp Dergisi. 2023; 62(2): 266 - 271.
Vancouver	ARSLAN DAVULCU E,Keklik Karadağ f,Arslan A,Demirci Z,DEMIR D,Soyer N,Sahin F,Saydam G Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. Ege Tıp Dergisi. 2023; 62(2): 266 - 271.
IEEE	ARSLAN DAVULCU E,Keklik Karadağ f,Arslan A,Demirci Z,DEMIR D,Soyer N,Sahin F,Saydam G "Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data." Ege Tıp Dergisi, 62, ss.266 - 271, 2023.
ISNAD	ARSLAN DAVULCU, EREN vd. "Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data". Ege Tıp Dergisi 62/2 (2023), 266-271.